107 related articles for article (PubMed ID: 15667002)
21. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
Benoy I; Salgado R; Colpaert C; Weytjens R; Vermeulen PB; Dirix LY
Clin Breast Cancer; 2002 Jan; 2(4):311-5. PubMed ID: 11899364
[TBL] [Abstract][Full Text] [Related]
22. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?
George ML; Eccles SA; Tutton MG; Abulafi AM; Swift RI
Clin Cancer Res; 2000 Aug; 6(8):3147-52. PubMed ID: 10955796
[TBL] [Abstract][Full Text] [Related]
23. Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport.
Wu FT; Stefanini MO; Mac Gabhann F; Kontos CD; Annex BH; Popel AS
Physiol Genomics; 2009 Jun; 38(1):29-41. PubMed ID: 19351908
[TBL] [Abstract][Full Text] [Related]
24. Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A.
Pietrowski D; Szabo L; Sator M; Just A; Egarter C
Hum Reprod; 2012 Jan; 27(1):196-9. PubMed ID: 22016416
[TBL] [Abstract][Full Text] [Related]
25. [Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer].
Swidzińska E; Ossolińska M; Naumnik W; Izycki T; Kucejko W; Chyczewska E
Pneumonol Alergol Pol; 2004; 72(9-10):389-94. PubMed ID: 16021992
[TBL] [Abstract][Full Text] [Related]
26. Elevated plasma levels of tissue factor as a valuable diagnostic biomarker with relevant efficacy for prediction of breast cancer morbidity.
Zarychta E; Rhone P; Bielawski K; Rosc D; Szot K; Zdunska M; Ruszkowska-Ciastek B
J Physiol Pharmacol; 2018 Dec; 69(6):. PubMed ID: 30802214
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers.
Vodolazkaia A; Yesilyurt BT; Kyama CM; Bokor A; Schols D; Huskens D; Meuleman C; Peeraer K; Tomassetti C; Bossuyt X; Lambrechts D; D'Hooghe T; Fassbender A
Fertil Steril; 2016 Apr; 105(4):988-96. PubMed ID: 26773192
[TBL] [Abstract][Full Text] [Related]
28. Disruption of components of vascular endothelial growth factor angiogenic signalling system in metabolic syndrome. Findings from a study conducted in rural Bangladeshi women.
Jesmin S; Akter S; Rahman MM; Islam MM; Islam AM; Sultana SN; Mowa CN; Yamaguchi N; Okazaki O; Satoru K; Kimura S; Hiroe M; Mizutani T; Moroi M
Thromb Haemost; 2013 Apr; 109(4):696-705. PubMed ID: 23364276
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Berezowska A; Radziszewski J; Bidzinski M; Kowalska M
PLoS One; 2017; 12(10):e0184576. PubMed ID: 28991928
[TBL] [Abstract][Full Text] [Related]
30. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.
Salven P; Orpana A; Joensuu H
Clin Cancer Res; 1999 Mar; 5(3):487-91. PubMed ID: 10100697
[TBL] [Abstract][Full Text] [Related]
31. Are the maternal and umbilical VEGF-A and SVEGF-R1 altered in pregnancies complicated by preeclampsia with or without intrauterine foetal growth retardation? Preliminary communication.
Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J
Med Wieku Rozwoj; 2008; 12(1):499-506. PubMed ID: 18663270
[TBL] [Abstract][Full Text] [Related]
32. Analysis of circulating vascular endothelial growth factor and its soluble receptors in patients with different forms of chronic urticaria.
Jagodzinska J; Polaniak R; Birkner E; Kasperska-Zajac A
Biomed Res Int; 2015; 2015():578383. PubMed ID: 25756047
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF.
Manau D; Fábregues F; Peñarrubia J; Creus M; Carmona F; Casals G; Jiménez W; Balasch J
Hum Reprod; 2007 Mar; 22(3):669-75. PubMed ID: 17079244
[TBL] [Abstract][Full Text] [Related]
34. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets.
Werther K; Christensen IJ; Nielsen HJ
Scand J Clin Lab Invest; 2002; 62(5):343-50. PubMed ID: 12387579
[TBL] [Abstract][Full Text] [Related]
35. [Association between elevated serum VEGF and polarographically measured tumor hypoxia in head and neck carcinomas].
Becker A; Stadler P; Krause U; Utzig D; Hänsgen G; Lautenschläger C; Rath FW; Molls M; Dunst J
Strahlenther Onkol; 2001 Apr; 177(4):182-8. PubMed ID: 11370552
[TBL] [Abstract][Full Text] [Related]
36. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Riethdorf S; Pantel K; Rack B; Janni W; Fasching PA; Aktas B; Kasimir-Bauer S; Hartkopf A; Solomayer EF; Fehm T; Müller V
Breast Cancer Res Treat; 2018 Nov; 172(1):93-104. PubMed ID: 30003393
[TBL] [Abstract][Full Text] [Related]
37. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.
Wu FT; Stefanini MO; Mac Gabhann F; Kontos CD; Annex BH; Popel AS
J Cell Mol Med; 2010 Mar; 14(3):528-52. PubMed ID: 19840194
[TBL] [Abstract][Full Text] [Related]
38. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer.
Li L; Wang L; Zhang W; Tang B; Zhang J; Song H; Yao D; Tang Y; Chen X; Yang Z; Wang G; Li X; Zhao J; Ding H; Reed E; Li QQ
Anticancer Res; 2004; 24(3b):1973-9. PubMed ID: 15274387
[TBL] [Abstract][Full Text] [Related]
39. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?
Lee JK; Hong YJ; Han CJ; Hwang DY; Hong SI
Int J Oncol; 2000 Jul; 17(1):149-52. PubMed ID: 10853032
[TBL] [Abstract][Full Text] [Related]
40. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
